Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of NGM/EE tablets manufactured at Schaffhausen versus Manati
NL-OMON40931Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of norgestimate, ethinyl estradiol and norelgestromin in contraception (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Bioequivalence of norgestimate, norelgestromin, and ethinyl estradiol, Safety and 1 more. Started Jun 2014; status: active, not recruiting.
02
Drugs
norgestimateethinyl estradiolnorelgestromin
03
Conditions
contraception
Beyond the preview
Go deeper on NL-OMON40931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40931.